The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
about
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studiesMesenchymal stem cells and immunomodulation: current status and future prospectsBioprocessing strategies for the large-scale production of human mesenchymal stem cells: a reviewMesenchymal stem/stromal cells as a delivery platform in cell and gene therapiesProgress of mesenchymal stem cell therapy for neural and retinal diseasesOptimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cellsHuman mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trialsHuman Adipose-Derived Stem Cells Expanded Under Ambient Oxygen Concentration Accumulate Oxidative DNA Lesions and Experience Procarcinogenic DNA Replication StressEfficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System.Manufacturing and banking of mesenchymal stem cells.Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cellsCD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacitiesMesenchymal stem cells in multiple sclerosis - translation to clinical trialsHarnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis.Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.Translational research in Huntington's disease: opening up for disease modifying treatmentReverse engineering human neurodegenerative disease using pluripotent stem cell technology.Gender difference in the neuroprotective effect of rat bone marrow mesenchymal cells against hypoxia-induced apoptosis of retinal ganglion cells.The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.Concise review: mesenchymal stem cells and translational medicine: emerging issues.Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage.Mesenchymal stem cells: a new trend for cell therapy.From tendon to nerve: an MSC for all seasons.Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?Perivascular mesenchymal stem cells in the adult human brain: a future target for neuroregeneration?Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.Large-scale production of human mesenchymal stem cells for clinical applications.Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles.Genetic and epigenetic instability of stem cells.Clinical Trials With Mesenchymal Stem Cells: An Update.In vivo quantitative assessment of cell viability of gadolinium or iron-labeled cells using MRI and bioluminescence imaging.Recent advances in the management of choreas.The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis.Mammalian MSC from selected species: Features and applications.CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases.Stirred tank bioreactor culture combined with serum-/xenogeneic-free culture medium enables an efficient expansion of umbilical cord-derived mesenchymal stem/stromal cells.Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells.The immunologic and hematopoietic profiles of mesenchymal stem cells derived from different sections of human umbilical cord.Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy.Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization
P2860
Q26750597-E506F964-EE9B-4554-97BD-61EFCA45AB3EQ26770191-BF6CCD01-ED59-4D58-9D30-94663E0AD594Q26776414-7C570185-9C97-40A0-88D9-84A1B334733FQ26799107-53CB9DB1-3376-4903-A1B7-41F6A8B1E32BQ27015716-ED016CEE-6D42-4DFE-A522-E002472C7A3DQ27015774-0ECE8561-E364-458E-B77E-67D99FEA6DBCQ28071916-AC1788DE-A93A-417E-A2EC-E8DA9DC9CD13Q33722201-0582BDD8-3881-4B7E-B478-D41964F40A39Q33864713-A46119B8-0710-445E-BE4C-1F4EBF965285Q34323739-8CD1DE88-FD88-47C5-BDE1-742A9552DDEFQ34768188-8DF378BA-FB03-4937-869C-20E002A33E59Q35017103-94EB2A60-650F-4C97-9B13-1AECAFA2701EQ35422678-71A7532C-6B92-4BD2-B7DB-9526A0C1FA34Q35603241-04B524BC-B77E-4538-A389-B01A55D768BCQ35757641-8F548DDC-A673-4F36-AB46-6023BA3CEAE8Q36722683-306CC6B7-15DA-496E-8447-13FAE1C5C690Q36734551-67244544-9640-4E9F-9244-CDE47ABE5992Q36996649-56E0EF28-51C0-4F77-A1A3-412489C6D82DQ37003127-031DFEC9-C74B-4B38-B277-231B57BAC291Q37056276-2EF5F74F-186F-44C5-9FE3-DBF270140064Q37677012-8FD22B2E-3198-40B2-BB36-7FAFEB57DE33Q37729093-57F0FE5E-5F28-48F8-8E1B-2848127733D9Q37989191-52CADE36-F5D7-49D0-8F16-D769E4EA4AF6Q37991400-24719953-1F0F-472D-872D-63D414DE9550Q38078084-B415AA08-8664-4280-94C8-630684DB781BQ38098448-5DDC894E-3AA3-416C-9665-60EADF5F8927Q38099034-A1FA3343-292F-4661-B73C-27B7AE5AA900Q38165464-E512904A-8A4A-4DBD-A7CF-EC5F93BE925CQ38195438-75E1D2C3-A22B-4A81-B042-77BC5D1A4AC8Q38596084-4950B35E-26F5-4E7E-98D2-BA93F777DD29Q39217789-817489CE-9B10-43BB-9924-1CF183CB0DEDQ42143817-4417C816-9BBC-4644-94A3-5FC0B6B0B857Q44239818-3A6C792F-2094-482A-BEFE-194139EE6BFCQ46307085-2439C57A-298D-4E78-97BB-388C5E6FF865Q49541054-015745F1-3AB3-475D-AA63-28844A78B485Q51335986-BF2D64AD-0996-4BA6-8B96-59679AD6893AQ52729545-EFD1E732-45F8-4260-B9D7-2B66A7AE2C6AQ54185892-BBF648B4-5F52-4606-AF2B-0918B6DB6764Q54996009-C4933954-578E-4D20-841E-59C38F0BC8CFQ58855503-4817E7EF-CBA8-4F82-9367-A36A6891B9FE
P2860
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The mesenchymal stem cells in ...... th blinded outcome assessments
@ast
The mesenchymal stem cells in ...... th blinded outcome assessments
@en
The mesenchymal stem cells in multiple sclerosis
@nl
type
label
The mesenchymal stem cells in ...... th blinded outcome assessments
@ast
The mesenchymal stem cells in ...... th blinded outcome assessments
@en
The mesenchymal stem cells in multiple sclerosis
@nl
prefLabel
The mesenchymal stem cells in ...... th blinded outcome assessments
@ast
The mesenchymal stem cells in ...... th blinded outcome assessments
@en
The mesenchymal stem cells in multiple sclerosis
@nl
P2093
P2860
P50
P356
P1433
P1476
The mesenchymal stem cells in ...... th blinded outcome assessments
@en
P2093
Andrew W Michell
Charles Crawley
Claudia A M Wheeler-Kingshott
Daniel J Tozer
Daniel J Webber
Daniel R Altmann
David H Miller
Karen Richardson
Kelly Barber
Madhan Kolappan
P2860
P2888
P356
10.1186/1745-6215-12-62
P577
2011-03-02T00:00:00Z
P5875
P6179
1052087913